Breast Cancer News

Piqray® approved for the treatment of postmenopausal women with breast cancer (May 29, 2019)

The US Food and Drug Administration (FDA) has approved Piqray® (alpelisib, formerly BYL719) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2... Continue Reading

Subcutaneous Herceptin Effective Option for Women With HER2-positive Breast Cancer (May 6, 2019)

One year of IV Herceptin (trastuzumab) is the standard of care for women with HER2-positive early stage breast cancer (ESBC). Doctors from Germany have confirmed that Herceptin can safely be administered subcutaneously without compromising effectiveness... Continue Reading

37,000 Patient Meta-Analyses Confirms Benefit of Dose Dense Therapy for Treatment of Early Stage Breast Cancer (April 30, 2019)

According to the National Cancer Institute the overall results of studies designed to compare dose dense therapy to every 3 week therapy support the use of dose-dense chemotherapy for the treatment of women with HER2-negative early stage breast cancer... Continue Reading

Dose Intense Chemotherapy Improves Survival When Used For Treatment of Early Stage Breast Cancer (April 8, 2019)

Giving chemotherapy drugs every two weeks instead of every three weeks reduces the risk of breast cancer recurrence and death in women undergoing adjuvant chemotherapy for early stage breast cancer. The analyses was performed by British physicians in... Continue Reading

Immunotherapy Offers New Hope in Triple Negative Breast Cancer (December 28, 2018)

Results from the Impassion 130 clinical trial published in the New England Journal of Medicine have demonstrated that immunotherapy can improve survival in breast cancer, especially in anti-programmed cell death ligand 1 (PD-1+) patients.  The results... Continue Reading

Herceptin Biosimilar Herzuma Approved for Certain Breast Cancer Indications (December 21, 2018)

The FDA has approved Celltrion and Teva’s Herzuma (trastuzumab-pkrb), a biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive breast cancer. Herzuma is the second oncology biosimilar approval in the United States in the past... Continue Reading

Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer (December 19, 2018)

SAN ANTONIO — Patients with triple-negative breast cancer who delayed starting adjuvant chemotherapy for more than 30 days after surgery were at significantly higher risk for disease recurrence and death compared with those who started the treatment... Continue Reading

Trastuzumab emtansine Improves Treatment of Early Stage HER 2-positive Breast Cancer (December 12, 2018)

Adjuvant trastuzumab emtansine showed improved disease-free survival compared with trastuzumab in HER2-positive early breast cancer. Patients with HER 2-positive early stage breast cancer with residual disease who received adjuvant trastuzumab emtansine... Continue Reading

Oxybutynin Decreased Frequency of Hot Flashes, Improved Quality of Life for Breast Cancer Survivors (December 11, 2018)

Treatment with oxybutynin helped reduce the frequency and intensity of hot flashes for women who could not take hormone replacement, including breast cancer survivors, according to results of a trial presented at the 2018 San Antonio Breast Cancer Symposium,... Continue Reading

Choice of surgery may affect quality of life for young breast cancer survivors (December 10, 2018)

Even as more young women with breast cancer opt to have mastectomies, many experience a persistent decline in their sexual and psychosocial well-being following the procedure, as detailed in new research by Dana-Farber/Brigham and Women’s Cancer Center.... Continue Reading

Latest Breast Cancer News By Stage


Carcinoma In Situ Breast cancer

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading

Quality of Life Helps Determine Type of Hormone Treatment in Early Breast Cancer (January 20, 2016)

Quality of life issues and different side effects caused by treatment may help determine which type of hormone therapy is most appropriate for postmenopausal women with ductal carcinoma in situ, particularly among women 60 years of age or older. These... Continue Reading

Radiation Essential to Controlling Long-Term Recurrence in Women With Early Form of Breast Cancer (October 1, 2015)

Doctors have reported that rates of breast cancer recurrences continue to increase, even after 12 years, among patients with ductal carcinoma in situ (DCIS) who do not receive radiation therapy as part of their treatment regimen. These results were recently... Continue Reading

Biomarker May Help Improve Treatment of Triple-Negative Breast Cancer (September 8, 2015)

Researchers have found a biomarker that appears active in the growth and spread of triple-negative breast cancer. Known as interleukin-13 receptor alpha 2 (IL13Ralpha2), the biomarker may help doctors identify patients at high risk of disease spread and... Continue Reading

Women with Early Breast Cancer Have Fewer Side Effects with Shorter Courses of Radiation (September 1, 2015)

Women with early breast cancer have fewer side effects when they’re treated with shorter courses of radiation at higher doses than with conventional radiation to the whole breast. These findings were reported in JAMA Oncology.[1] Treatment with shorter... Continue Reading

More Carcinoma In Situ Breast cancer

Inflammatory Breast Cancer

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading

Breast Cancer Research: Have We Made Progress? (January 27, 2015)

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included the following key developments: 2014: Have we... Continue Reading

Walk or Run Your Way to a Reduced Risk of Breast Cancer (September 24, 2014)

Want to reduce your risk of breast cancer? Lace up those shoes and get moving—because exercise has a significant impact. There is a growing body of evidence to indicate that exercise is crucial to reducing the risk of cancer. Now a new study has put... Continue Reading

Risk of Breast Cancer Recurrence Doesn’t Increase with TNF Inhibitor Use (August 28, 2014)

According to the results of a recently published study from Swedish investigators treatment with tumor necrosis factor inhibitors (TNF) does not appear to increase the rate of breast cancer recurrence among patients with rheumatoid arthritis (RA).  The... Continue Reading

Ask the Expert: Making Informed Decisions about Breast Reconstruction (June 18, 2014)

July 16, 2014 at 6:30pm EST CancerConnect live Web Chat with an Expert series presents:  “Making Informed Decisions about Breast Reconstruction.”  On July 16, 2014 at 6:30pm EST you will have the opportunity to engage with a breast cancer expert... Continue Reading

More Inflammatory Breast Cancer

Metastatic Breast Cancer

FDA approves new treatment for certain advanced or metastatic breast cancers (October 5, 2017)

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed... Continue Reading

FDA Grants Breakthrough Therapy Designation to DS-8201 for HER2-Positive Metastatic Breast Cancer (August 30, 2017)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), for the treatment of patients with HER2-positive, locally advanced or metastatic breast... Continue Reading

Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer (March 16, 2017)

The US Food and Drug Administration (FDA) has approved the investigational drug Kisqali® (ribociclib, LEE011) for first line treatment of hormone receptor + HER 2- metastatic breast cancer because when combined with Femera (letrozole) the combination... Continue Reading

Keytruda®/Halaven® Combo May Be Effective in Advanced Triple-Negative Breast Cancer (January 9, 2017)

The investigative treatment combination including Keytruda® (pembrolizumab) plus Halaven® (eribulin) could provide a potential therapeutic option for patients with advanced triple-negative breast cancer (TNBC) whose disease has advanced following prior... Continue Reading

Ribociclib Offers ‘Paradigm Shift’ in Advanced Breast Cancer (October 26, 2016)

The investigational drug ribociclib (formerly LEE011) when combined with Femera (letrozole) for the initial treatment of postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer leads to improved survival without cancer recurrence. The... Continue Reading

More Metastatic Breast Cancer

Recurrent Breast Cancer

Tecentriq™ Plus Abraxane® Effective Combo in Difficult to Treat Breast Cancer (June 30, 2016)

The combination of the immune stimulating agent Tecentriq™ (atezolizumab), plus the chemotherapy agent Abraxane® (nab-paclitaxel) is effective in providing anti-cancer responses among patients with advanced triple-negative breast cancer (TNBC). These... Continue Reading

Directly Involving Patients Drives Participation in Metastatic Breast Cancer Study (June 22, 2016)

A clinical study to accelerate research in metastatic breast cancer has rapidly enrolled participants through direct collaboration with patients. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology... Continue Reading

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading

Blood Test May Predict Cancer Recurrences Earlier than Standard Methods (October 26, 2015)

A blood test that can detect circulating DNA from cancer cells appears to accurately predict the risk of a breast cancer recurrence 8 months earlier than standard detection methods among women with high-risk breast cancer. However, further study is necessary... Continue Reading

Abemaciclib Receives FDA Breakthrough Therapy Designation in Advanced Breast Cancer (October 9, 2015)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. According... Continue Reading

More Recurrent Breast Cancer

Screening/Prevention Breast Cancer

It’s in the Genes: Top 5 Things to Know about Genetic Testing (July 8, 2016)

Advances in genetic testing are offering women more information than ever before about their genetic makeup and are providing opportunities for empowered decision-making related to a wide range of health issues. In this recurring column, experts provide... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its... Continue Reading

3D Mammography Proves More Accurate in Breast Cancer Detection (March 31, 2016)

Longer follow-up evaluating digital breast tomosynthesis (DBT), also referred to as 3D mammography, demonstrates its continued effectiveness compared to standard digital mammography (DM) when screening for breast cancer. These results were recently published... Continue Reading

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading

Blood Test May Predict Cancer Recurrences Earlier than Standard Methods (October 26, 2015)

A blood test that can detect circulating DNA from cancer cells appears to accurately predict the risk of a breast cancer recurrence 8 months earlier than standard detection methods among women with high-risk breast cancer. However, further study is necessary... Continue Reading

More Screening/Prevention Breast Cancer

Stage I Node Negative Breast Cancer

MammaPrint Might Help Identify Breast Cancer Patients Who Could Safely Opt Out of Chemo (September 7, 2016)

MammaPrint, a 70-gene signature test, might help healthcare providers and patients determine whether they will derive a benefit from chemotherapy, or if they could safely choose to not receive chemotherapy for early-stage breast cancer. These results... Continue Reading

Neratinib Improves Cancer-Free Survival in Early Breast Cancer (July 27, 2016)

The targeted agent neratinib (PB272), which is still in clinical trials, demonstrated an improvement in cancer-free survival when used after Herceptin® (trastuzumab) in early-stage, HER2-positive breast cancer. Approximately 20-30% of breast cancer is... Continue Reading

Treatment with Aromatase Inhibitors for 10 Years Improves Cancer-Free Survival in Breast Cancer (June 7, 2016)

Among postmenopausal women with hormone-positive, early breast cancer, treatment with aromatase inhibitors (AIs) for 10 years significantly improves cancer-free survival, compared to the 5-year standard length of AI treatment.  However, quality of life... Continue Reading

Some Premenopausal Women Benefit from Exemestane Compared to Tamoxifen (April 28, 2016)

Among premenopausal women with hormone-positive, early breast cancer who are considered to have a high risk of a cancer recurrence, the use of Aromasin® (exemestane) versus tamoxifen improves cancer-free survival at 5 years. These results were recently... Continue Reading

Dose-Dense Chemotherapy for Premenopausal Breast Cancer Improves Survival (March 28, 2016)

Premenopausal women who have been diagnosed with breast cancer have improved survival if their chemotherapy doses are delivered every two weeks, compared to every three weeks. These results were recently presented at the 2016 European Breast Cancer Conference... Continue Reading

More Stage I Node Negative Breast Cancer

Stages II-III Breast Cancer

Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer (March 16, 2017)

The US Food and Drug Administration (FDA) has approved the investigational drug Kisqali® (ribociclib, LEE011) for first line treatment of hormone receptor + HER 2- metastatic breast cancer because when combined with Femera (letrozole) the combination... Continue Reading

Neratinib Improves Cancer-Free Survival in Early Breast Cancer (July 27, 2016)

The targeted agent neratinib (PB272), which is still in clinical trials, demonstrated an improvement in cancer-free survival when used after Herceptin® (trastuzumab) in early-stage, HER2-positive breast cancer. Approximately 20-30% of breast cancer is... Continue Reading

Some Premenopausal Women Benefit from Exemestane Compared to Tamoxifen (April 28, 2016)

Among premenopausal women with hormone-positive, early breast cancer who are considered to have a high risk of a cancer recurrence, the use of Aromasin® (exemestane) versus tamoxifen improves cancer-free survival at 5 years. These results were recently... Continue Reading

Dose-Dense Chemotherapy for Premenopausal Breast Cancer Improves Survival (March 28, 2016)

Premenopausal women who have been diagnosed with breast cancer have improved survival if their chemotherapy doses are delivered every two weeks, compared to every three weeks. These results were recently presented at the 2016 European Breast Cancer Conference... Continue Reading

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading

More Stages II-III Breast Cancer

Supportive Care Breast Cancer

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading

Breast Cancer Research: Have We Made Progress? (January 27, 2015)

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included the following key developments: 2014: Have we... Continue Reading

Risk of Breast Cancer Recurrence Doesn’t Increase with TNF Inhibitor Use (August 28, 2014)

According to the results of a recently published study from Swedish investigators treatment with tumor necrosis factor inhibitors (TNF) does not appear to increase the rate of breast cancer recurrence among patients with rheumatoid arthritis (RA).  The... Continue Reading

Ask the Expert: Making Informed Decisions about Breast Reconstruction (June 18, 2014)

July 16, 2014 at 6:30pm EST CancerConnect live Web Chat with an Expert series presents:  “Making Informed Decisions about Breast Reconstruction.”  On July 16, 2014 at 6:30pm EST you will have the opportunity to engage with a breast cancer expert... Continue Reading

Ask the Expert: Breast Cancer, Diet and Exercise (May 19, 2014)

CancerConnect recently partnered with Dana-Farber to provide you with the opportunity to engage with a breast cancer expert, Jennifer A. Ligibel, MD, of the Susan F. Smith Center for Women’s Cancers at Dana-Farber. On May 7 and 8, 2014, Dr. Ligibel... Continue Reading

More Supportive Care Breast Cancer